secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001104659-25-111310
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026
---------------------------------------------------------------

- Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.
- Phase 2 REVERT Liver Cancer (TTI-101) topline data expected H1 2026; interim showed activity.
- TTI-109 healthy volunteer study started; results also H1 2026.
- REVERT IPF trial preliminary data in October did not meet goals; further analysis underway.
- R&D expenses $3.6M, down from $4.8M; G&A $2.3M, up from $0.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/0001104659-25-111310-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465925111310/tm2531079d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-111310

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer